CUA Educational Tools

CUA Management Tool Kits

Enfortumab Vedotin (EV) and Pembrolizumab (Pembro) Combination Treatment for Patients
with Urological Cancers – Adverse Events (AEs) / Traitement d’association par enfortumab védotin (EV) et pembrolizumab (pembro) dans les cas de cancers urologiques — Manifestations indésirables (MI)

Also available at: https://cuaevpaetool.ca/